Abstract: System and methods for recycling a material comprising a polymer in an expanded state is disclosed. The system can include a shredder, a heating chamber operatively connected to the shredder, a condenser operatively connected to the heating chamber, a solvent tank operatively connected to the condenser, and a circulation unit operatively connected to the solvent tank and the heating chamber.

Abstract: The present disclosure relates to sealed isocyanate resin compositions. The resin compositions may be used for additive manufacturing. One embodiment of the invention includes a photopolymerizable resin for additive manufacturing, the resin comprising: a blocked isocyanate; at least one monomer or oligomer; and a multifunctional nucleophile.

Abstract: Provided herein are tumor-antigen VGLL 1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL 1 are also provided.

Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: In one embodiment, a mixing device includes a sleeve that forms an inner space configured to receive a sample container, a housing associated with the sleeve, a mixing element contained within the housing that is configured to mix liquid contained within the sample container, and an activation element configured to activate the mixing element when the activation element is triggered.

Abstract: Provided herein are methods of detecting pancreatic cancer, particularly early stage pancreatic cancer, comprising measuring the expression of the biomarker panel TNC-FN III-C, TFPI, and CA19-9. The expression may be determined by an ELISA, such as a multiplex ELISA. Further provided herein are methods of treating subjects identified to have pancreatic cancer.

Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

Abstract: The present disclosure provides pharmaceutical compositions for monoclonal antibodies, antibody-related products, therapeutic proteins, peptides and other biopharmaceuticals. The compositions provide initial and long term stability of the biopharmaceutical agent, rendering them suitable for parenteral, pulmonary, transdermal, topical, intradermal, intrascleral, intracorneal, ocular and other forms of delivery. The compositions and methods lead to higher yields in dilute solutions and reduce unwanted aggregation of the biopharmaceutical agent. The compositions and methods also allow for disaggregation of previously aggregated proteins and protection from aggregation upon dilution. Additionally, provided are non-aggregating antibody reagents for analytical immunoassays including ELISA methods. The invention provides compositions and methods for topical, enteral, parenteral, pulmonary and other forms of delivery of biologically active substances.

Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.

Abstract: A method of producing aluminum chlorohydrate comprises adding small form aluminum metal pellets to a reactant receiving space of a reactor tank to form a pellet bed; adding aqueous hydrochloric acid to the reactant receiving space of the reactor tank; and continuously circulating the aqueous hydrochloric acid through the pellet bed. In some embodiments, the continuously circulating aqueous hydrochloric acid dispels reaction gases from the pellet bed. Methods described herein can, in some cases, further comprise consecutively adding additional small form aluminum metal pellets to the reactant receiving space of the reactor tank as the small form aluminum metal pellets are consumed in the pellet bed.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: DNA is sequenced by (a) independently sequencing first and second strands of a dsDNA to obtain corresponding first and second sequences; and (b) combining the first and second sequences to generate a consensus sequence of the dsDNA. By independently sequencing first and second strands the error probability of the consensus sequence approximates a multiplication of those of the first and second sequences.

Abstract: Methods and devices for the prevention, treatment and diagnosis of cancer include assessing and quantifying imperfect dsDNA break repair. The methods may include determining a deletion signal for a DNA-containing sample of a subject, wherein the deletion signal comprises distributions of deletions (frequencies) of deletions with microhomologies of different lengths at the deletion sites in a DNA sequence or genome of the subject or sample thereof. The method may further include decomposing the deletion signal into components corresponding to changes arising from: (1) DNA repair processes, (2) systematic effects due to mapping personal deletion variants to reference genomes, and (3) false positive deletions generated during sample preparation, sequencing, and analysis, and quantifying these components to produce mutational signatures of defective HRR.

Abstract: Certain aspects are directed to a housing and cap to provide protection of medical devices having one or more percutaneous connection (e.g., a three-way stopcock or catheter port).

Abstract: Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.

Abstract: Provided herein are CD79b antibodies and CD79b-specific chimeric antigen receptors (CARs). Further provided herein are immune cells expressing the CD79b-specific CARs and methods of treating cancer by administering the CD79b-specific CAR immune cells.

Abstract: The current disclosure provides for novel therapeutic methods by identifying cancer patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after the subject has been determined to have increased expression of CXCL13 in a biological sample from the subject.